Third quarter:

• Sales amounted to SEK 177 (125) million, corresponding to an increase of 41 percent in SEK. Sales growth was 29 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 25 million to sales. Adjusted for this, sales growth amounted to 11 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 82 (49) million, corresponding to a margin of 46 (39) percent. Income was positively affected by the recovered additional purchase price for the acquisition of Cryo Innovation to the tune of SEK 17 million. Adjusted for this one-time item, EBITDA amounted to SEK 65 million, corresponding to a margin of 37 percent. Fluctuations in exchange rates had a positive effect of SEK 10 million on EBITDA.  
• Net income amounted to SEK 52 (36) million, which gave earnings per share of SEK 2.41 (1.79).

January-September:

• Sales amounted to SEK 523 (374) million, corresponding to an increase of 40 percent in SEK. Sales growth was 25 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 79 million to sales. Adjusted for this, sales growth amounted to 6 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 198 (123) million, corresponding to a margin of 38 (33) percent. Income was positively affected by the recovered additional purchase price for the acquisition of Cryo Innovation to the tune of SEK 17 million. Adjusted for this one-time item, EBITDA amounted to SEK 181 million, corresponding to a margin of 35 percent. Fluctuations in exchange rates had a positive effect of SEK 30 million on EBITDA.  
• Net income amounted to SEK 126 (81) million, which gave earnings per share of SEK 5.79 (4.07).

Gothenburg, November 5, 2015
VITROLIFE AB (publ)
Thomas Axelsson, CEO